LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
Wesley Hamilton, Crossfit partner on gym space flexing adaptive athletes alongside able-bodied peers
A first-of-its-kind, all-inclusive gym is emerging to reshape what fitness feels like for adaptive athletes, said Wesley Hamilton. “This vision of what we’re about to create here at Crossfit Memorial Hill is magnificent,” said Hamilton, founder and executive director of Kansas City-based nonprofit the Disabled But Not Really Foundation (DBNR), which partnered with the local…
With final flourishes under way, Plexpod River Market opening expected within weeks
Plexpod River Market might be weeks away from opening, but the coworking community’s new location on the KC Streetcar line already is sparking interest among startups, said Gerald Smith. “Magic happens when these entrepreneurs have a platform where they can connect — that’s where sparks fly,” said Smith, co-founder of Plexpod. “The more we can…
How ‘compassion fatigue’ led a TV journalist to bring Healium VR therapy to market
Distress calls poured over the newsroom scanner near Sarah Hill’s desk, day in and day out for 20 years. Each one seemingly growing darker than the last, she recalled. “I was a television journalist. … You have to cover a lot of trauma and a lot of really bad stuff,” said Hill, founder of Healium…
Community rallies behind Chris Goode after ‘violating’ overnight Ruby Jean’s break-in
Chris Goode isn’t angry, the Ruby Jean’s founder said after an overnight break-in left shattered glass and an empty cash register at his juicery and kitchen on Troost. “When trials come, maintain the faith and just keeping pressing forward,” Goode said. “People responded to that message pretty quickly. We know that the business is supported…